Science & Tech · AI · 3 hrs ago
Anthropic enters drug development with rare-disease treatment effort
Anthropic has entered drug development, announcing the move on October 27.
The US company plans to hire people to work on medicines for rare diseases, which affect relatively small groups of patients.
It has bought Mithril Medicine, a US startup developing treatments for two types of muscular dystrophy.
Mithril had one full-time employee and used AI in its research.
Anthropic plans to use its Claude AI to speed up development.
The company says it hopes to begin clinical trials as early as 2028.
Anthropic announced it had entered drug development and acquired Mithril Medicine, a startup working on treatments for two rare forms of muscular dystrophy.
The company plans to use its Claude AI system to speed up drug development.
Anthropic said it may begin clinical trials as early as 2028.
It also reported early results from Claude-assisted drug development work with six outside organizations.
Mithril Medicine had one full-time employee.
- Who
- Anthropic and Mithril Medicine. Anthropic also reported work with six outside organizations.
- What
- Anthropic acquired Mithril Medicine and entered drug development, focusing on treatments for two rare forms of muscular dystrophy.
- When
- Anthropic announced the move on Oct. 27, 2026.
- Where
- Not stated.
- Why
- Anthropic plans to use Claude to speed up drug development.
This story does not have two clearly opposing sides.
Anthropic announced it had entered drug development and acquired Mithril Medicine.
Anthropic released early results from Claude-assisted drug development work with six outside organizations.
Anthropic said it may begin clinical trials as early as this year.
- Acquired startup
- Mithril Medicine
- Conditions targeted
- Two rare forms of muscular dystrophy
- Mithril staffing
- One full-time employee
- Potential trial start
- As early as 2028
- Outside organizations
- Six
- Partners
- BigHat Biosciences; Bristol Myers Squibb; Divergence Labs; Enveda; Generate Biomedicines; the Column Group